CN114409754A - 一种微电压方法协同抗菌肽pv-q5及其用途 - Google Patents
一种微电压方法协同抗菌肽pv-q5及其用途 Download PDFInfo
- Publication number
- CN114409754A CN114409754A CN202111659224.XA CN202111659224A CN114409754A CN 114409754 A CN114409754 A CN 114409754A CN 202111659224 A CN202111659224 A CN 202111659224A CN 114409754 A CN114409754 A CN 114409754A
- Authority
- CN
- China
- Prior art keywords
- peptide
- antibacterial peptide
- antibacterial
- micro
- vibrio parahaemolyticus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003910 polypeptide antibiotic agent Substances 0.000 title claims abstract description 94
- 238000000034 method Methods 0.000 title abstract description 12
- 230000002195 synergetic effect Effects 0.000 title abstract description 12
- 241000607272 Vibrio parahaemolyticus Species 0.000 claims abstract description 38
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 10
- 239000005452 food preservative Substances 0.000 claims abstract description 6
- 235000019249 food preservative Nutrition 0.000 claims abstract description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims description 34
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims description 34
- 210000000170 cell membrane Anatomy 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 18
- 241000894006 Bacteria Species 0.000 claims description 15
- 230000001580 bacterial effect Effects 0.000 claims description 14
- 230000035699 permeability Effects 0.000 claims description 12
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 230000002147 killing effect Effects 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000000845 anti-microbial effect Effects 0.000 claims 2
- 238000009360 aquaculture Methods 0.000 claims 1
- 244000144974 aquaculture Species 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000011161 development Methods 0.000 abstract description 4
- 241000238553 Litopenaeus vannamei Species 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 102000007079 Peptide Fragments Human genes 0.000 description 6
- 108010033276 Peptide Fragments Proteins 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 244000000010 microbial pathogen Species 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000019331 Foodborne disease Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010005233 alanylglutamic acid Proteins 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000002983 circular dichroism Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- HHRAXZAYZFFRAM-CIUDSAMLSA-N Ala-Leu-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O HHRAXZAYZFFRAM-CIUDSAMLSA-N 0.000 description 1
- NZGRHTKZFSVPAN-BIIVOSGPSA-N Ala-Ser-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N NZGRHTKZFSVPAN-BIIVOSGPSA-N 0.000 description 1
- VRTOMXFZHGWHIJ-KZVJFYERSA-N Ala-Thr-Arg Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VRTOMXFZHGWHIJ-KZVJFYERSA-N 0.000 description 1
- JCAISGGAOQXEHJ-ZPFDUUQYSA-N Arg-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N JCAISGGAOQXEHJ-ZPFDUUQYSA-N 0.000 description 1
- GOWZVQXTHUCNSQ-NHCYSSNCSA-N Arg-Glu-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O GOWZVQXTHUCNSQ-NHCYSSNCSA-N 0.000 description 1
- WVNFNPGXYADPPO-BQBZGAKWSA-N Arg-Gly-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O WVNFNPGXYADPPO-BQBZGAKWSA-N 0.000 description 1
- ZJIFRAPZHAGLGR-MELADBBJSA-N Asn-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)N)N)C(=O)O ZJIFRAPZHAGLGR-MELADBBJSA-N 0.000 description 1
- KBQOUDLMWYWXNP-YDHLFZDLSA-N Asn-Val-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC(=O)N)N KBQOUDLMWYWXNP-YDHLFZDLSA-N 0.000 description 1
- VAWNQIGQPUOPQW-ACZMJKKPSA-N Asp-Glu-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O VAWNQIGQPUOPQW-ACZMJKKPSA-N 0.000 description 1
- SJLDOGLMVPHPLZ-IHRRRGAJSA-N Asp-Met-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SJLDOGLMVPHPLZ-IHRRRGAJSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010061166 Gastroenteritis bacterial Diseases 0.000 description 1
- HYPVLWGNBIYTNA-GUBZILKMSA-N Gln-Leu-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O HYPVLWGNBIYTNA-GUBZILKMSA-N 0.000 description 1
- KPNWAJMEMRCLAL-GUBZILKMSA-N Gln-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)N KPNWAJMEMRCLAL-GUBZILKMSA-N 0.000 description 1
- ZZLDMBMFKZFQMU-NRPADANISA-N Gln-Val-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O ZZLDMBMFKZFQMU-NRPADANISA-N 0.000 description 1
- OACPJRQRAHMQEQ-NHCYSSNCSA-N Gln-Val-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OACPJRQRAHMQEQ-NHCYSSNCSA-N 0.000 description 1
- CGOHAEBMDSEKFB-FXQIFTODSA-N Glu-Glu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O CGOHAEBMDSEKFB-FXQIFTODSA-N 0.000 description 1
- AUTNXSQEVVHSJK-YVNDNENWSA-N Glu-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O AUTNXSQEVVHSJK-YVNDNENWSA-N 0.000 description 1
- LGYZYFFDELZWRS-DCAQKATOSA-N Glu-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O LGYZYFFDELZWRS-DCAQKATOSA-N 0.000 description 1
- LHIPZASLKPYDPI-AVGNSLFASA-N Glu-Phe-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O LHIPZASLKPYDPI-AVGNSLFASA-N 0.000 description 1
- OLPPXYMMIARYAL-QMMMGPOBSA-N Gly-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)CN OLPPXYMMIARYAL-QMMMGPOBSA-N 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- HOLOYAZCIHDQNS-YVNDNENWSA-N Ile-Gln-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N HOLOYAZCIHDQNS-YVNDNENWSA-N 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KWTVLKBOQATPHJ-SRVKXCTJSA-N Leu-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(C)C)N KWTVLKBOQATPHJ-SRVKXCTJSA-N 0.000 description 1
- TWQIYNGNYNJUFM-NHCYSSNCSA-N Leu-Asn-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O TWQIYNGNYNJUFM-NHCYSSNCSA-N 0.000 description 1
- HKCCVDWHHTVVPN-CIUDSAMLSA-N Lys-Asp-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O HKCCVDWHHTVVPN-CIUDSAMLSA-N 0.000 description 1
- PBIPLDMFHAICIP-DCAQKATOSA-N Lys-Glu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PBIPLDMFHAICIP-DCAQKATOSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- KJJROSNFBRWPHS-JYJNAYRXSA-N Phe-Glu-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O KJJROSNFBRWPHS-JYJNAYRXSA-N 0.000 description 1
- POQFNPILEQEODH-FXQIFTODSA-N Pro-Ser-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O POQFNPILEQEODH-FXQIFTODSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- UKBSDLHIKIXJKH-HJGDQZAQSA-N Thr-Arg-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O UKBSDLHIKIXJKH-HJGDQZAQSA-N 0.000 description 1
- LAFLAXHTDVNVEL-WDCWCFNPSA-N Thr-Gln-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N)O LAFLAXHTDVNVEL-WDCWCFNPSA-N 0.000 description 1
- DJDSEDOKJTZBAR-ZDLURKLDSA-N Thr-Gly-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O DJDSEDOKJTZBAR-ZDLURKLDSA-N 0.000 description 1
- AYCQVUUPIJHJTA-IXOXFDKPSA-N Thr-His-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O AYCQVUUPIJHJTA-IXOXFDKPSA-N 0.000 description 1
- NWEGIYMHTZXVBP-JSGCOSHPSA-N Tyr-Val-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O NWEGIYMHTZXVBP-JSGCOSHPSA-N 0.000 description 1
- JTWIMNMUYLQNPI-WPRPVWTQSA-N Val-Gly-Arg Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCNC(N)=N JTWIMNMUYLQNPI-WPRPVWTQSA-N 0.000 description 1
- ABUBSBSOTTXVPV-UHFFFAOYSA-H [U+6].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O Chemical compound [U+6].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ABUBSBSOTTXVPV-UHFFFAOYSA-H 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 108010070783 alanyltyrosine Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000000978 circular dichroism spectroscopy Methods 0.000 description 1
- 238000001142 circular dichroism spectrum Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000003411 electrode reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 108010082286 glycyl-seryl-alanine Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 108010089198 phenylalanyl-prolyl-arginine Proteins 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010610 time kill assay Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Insects & Arthropods (AREA)
- Polymers & Plastics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种微电压方法协同抗菌肽PV‑Q5及其用途。微电压方法协同抗菌肽PV‑Q5的氨基酸序列如SEQ ID NO:5所示,其具有抗菌的用途。该抗菌肽在微电压协同作用下对副溶血性弧菌的抑菌效果有明显增强。本发明为后续进一步研究抗菌肽作为食品防腐剂开发奠定了基础。
Description
技术领域
本发明涉及生物技术领域,尤其涉及一种微电压方法协同抗菌肽PV-Q5及其用途。
背景技术
食品是人类赖以生存和发展的物质基础,食品安全不仅关乎广大人民群众的身体健康和切身利益,同时也关系到国家经济的稳步发展和社会的繁荣昌盛。致病性微生物是引起食源性疾病的重要因素,近年来,每年全球近15亿患食源性疾病的人群中,有70%是因为食品中的致病性微生物污染所导致。致病性微生物所引起的食源性疾病正严重威胁着人民的身体健康,阻碍社会经济发展。副溶血性弧菌是广泛存在于海产品中的食源性细菌之一,也是引起细菌性胃肠炎的主要原因。
微电压是一种通过外加弱电流激发电极反应以刺激微生物细胞,为提高细胞生长和活性提供了一条有效途径。目前,这一技术已在酵母发酵体系和生物脱氮体系中得到初步应用。通过研究发现,微电压刺激能够改变细菌细胞的增长,提高细胞增长速度。另一方面,现已有报道表明微电压亦可对微生物细胞施加负面影响,如在生物膜体系中施加微电压可显著提升灭菌剂的杀菌效果,影响细胞的生长代谢,改变细胞膜的通透性。然而,微电压的手段并不能够灭活病原微生物,但可以增效其他的抑菌方式来抑制细菌生长。
抗菌肽由生物体内免疫防御体系产生,是一类具有抵抗外源性病原菌的多肽类活性物质。由于细菌的外膜含有较多带负电荷的分子,如脂多糖、磷壁酸等,阳离子抗菌肽可通过静电吸引与膜成分相互作用,从而与细菌细胞膜结合,产生抑菌效果。自然界中的抗菌肽以动物源抗菌肽为主,因其具有广谱高效抗菌活性、细胞选择性及不易产生耐药性等特点,一向被认为是抗生素的理想替代品。在无脊椎动物的先天免疫系统中,抗菌肽是一种重要的免疫效应分子。
发明内容
本发明的目的在于提供一种微电压方法协同抗菌肽PV-Q5。
为实现上述目的,本发明提供一种抗菌肽PV-Q5,其特征在于,所述抗菌肽PV-Q5的氨基酸序列如SEQ ID NO:5所示。
本发明还保护所述抗菌肽PV-Q5用于抗菌的用途。
进一步,所述菌是指细菌。
进一步,所述细菌是指副溶血性弧菌和大肠杆菌。
进一步,所述抗菌是指抑制和/或杀灭副溶血性弧菌、大肠杆菌。
进一步,所述抗菌在微电压辅助处理下,具有增强的效果。
本发明还保护所述抗菌肽PV-Q5具有改变菌细胞膜表面通透性的用途。
本发明还保护所述抗菌肽PV-Q5用于制备抗菌药物、食品防腐剂和水产动物养殖饲料的用途。
本发明还保护一种抗菌药物,其特征在于,含有所述抗菌肽PV-Q5。
本发明还保护一种食品防腐剂,其特征在于,含有所述抗菌肽PV-Q5。
本发明预测并合成了对副溶血性弧菌具有弱抗菌活性的抗菌肽PV-Q5。然而,在通电的辅助下,肽PV-Q5的抗菌效果有了很大的提高,并对其协同作用机制进行了进一步的探讨。
本发明的目的在于提供一种微电压的辅助方法,并研究其对抗菌肽PV-Q5抑菌增效作用及其应用,通过微电压辅助增效抗菌肽对副溶血性弧菌的研究,为寻找新的食品添加剂杀菌技术供实验依据,促进我国食品行业健康、持续发展。
为了解决上述目的,本发明采用的技术方案如下:
抗菌肽PV-Q5,其氨基酸序列QVRNFPRGSAASPSALASPR,如SEQ ID NO:5所示。
以凡纳滨对虾(Penaeus vannamei)为目标寻找其序列中的抗菌肽存在可行的理论依据。因此,首先利用质谱和生物信息学对凡纳滨对虾的蛋白序列进行筛选,然后发现了一条对副溶血性弧菌具有抑制作用的抗菌肽序列QVRNFPRGSAASPSALASPR,命名PV-Q5,分子量为2068.1Da。
抗菌肽PV-Q5可以改变细菌细胞膜的通透性,并抑制细胞膜生成,降低细菌的存活率。
本发明的抗菌肽可以采用本领域技术人员已知的方法合成,例如固相合成,并采用本领域技术人员已知的方法进行纯化,例如高效液相色谱法。
实施本发明,具有如下有益效果:
本发明以副溶血性弧菌为研究对象,并通过质谱鉴定和生物信息学筛选,合成一个全新氨基酸序列的多肽PV-Q5。研究不同处理的抗菌肽PV-Q5对副溶血性弧菌的抑菌活性;并利用透射电镜观察抗菌肽PV-Q5对副溶血性弧菌和通电条件下的破坏程度;最后对抗菌肽PV-Q5的二级结构和三维模型进行验证。实验结果表明,微电压辅助处理的抗菌肽PV-Q5对副溶血性弧菌具有强烈的抑制作用。它的抑菌机理是与细菌细胞膜相互作用后改变其细胞膜的通透性,从而使得细菌走向凋亡。本发明为抗菌肽PV-Q5作为食品防腐剂提供了实验依据。
附图说明
图1为本发明抗菌肽PV-Q5的质谱图。
图2为本发明抗菌肽PV-Q5单独处理对副溶血性弧菌最低抑制浓度(MIC)测定对照图。
图3为本发明抗菌肽PV-Q5协同微电压处理对副溶血性弧菌最低抑制浓度(MIC)测定对照图。
图4为本发明抗菌肽PV-Q5对副溶血性弧菌孵育和微电压条件的时间杀伤测定曲线。
图5为本发明抗菌肽PV-Q5作用副溶血性弧菌的透射电镜观察图。
图6为本发明抗菌肽PV-Q5对副溶血性弧菌膜通透性变化折线图。
图7为本发明抗菌肽PV-Q5在SDS溶液和PBS溶液中的二级结构变化图。
图8为本发明抗菌肽PV-Q5的三维结构预测图。
具体实施方式
下面详细描述本发明的实施例,所述实施例的示例在附图中示出,其中自始至终相同或类似的标号表示相同或类似的元件或具有相同或类似功能的元件。下面通过参考附图描述的实施例是示例性的,旨在用于解释本发明,而不能理解为对本发明的限制。实施例中未注明具体技术或条件者,按照本领域内的文献所描述的技术或条件或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者,均为可以通过市购获得的常规产品。在下面的实施例中,如未明确说明,“%”均指重量百分比。
实施例1:凡纳滨对虾的高效液相色谱-质谱联用技术(UPLC-MS)
使用色谱仪Nano Aquity UPLC system(Waters Corp.)对分子量小于3kDa的对凡纳滨对虾虾液进行梯度洗脱,色谱条件:进样量:5.0μL。色谱柱:C18分析色谱柱,长度25cm,内径75μm。流动相:A:0.1%甲醇水溶液;B:乙腈。结合搜索软件在MAXQUANT v1.6.5.0在数据库中得到了10个蛋白质序列,对所得肽段进行质谱鉴定,肽段PV-Q5质谱结果如图1所示。
实施例2:凡纳滨对虾中抗菌肽的生物信息学筛选
通过高效液相色谱-质谱结果(质谱条件设置为翘气速率:40mL/min;辅助气速率:10mL/min;喷雾电压:3.0kV;毛细管温度:300℃、S-lens:50%;HCD:27%。扫描模式为正离子,Full ms→ddms2。一级扫描:分辨率70000,范围350~1600m/z;二级扫描:分辨率17500,fixed first mass 120m/z。Dynamic exclusion:10.0s)鉴定出10条肽段序列,肽段的片段平均长度为14.5,分子量在973-2116Da范围。利用在线软件APD3对10条肽段的电荷、疏水性进行分析,最终如表1所示,筛选出一条分子量为2068.1Da、疏水性为35%、电荷为+3、氨基酸序列为QVRNFPRGSAASPSALASPR(SEQ ID NO:5)的多肽进行化学合成(由北京中科亚光生物科技有限公司合成),并对其抑菌活性进行验证。
表1:凡纳滨对虾LCMS所得肽段分析结果表
实施例3:最低抑制浓度(MIC)测定
将副溶血性弧菌(ATCC 17802)在37℃培养12h至对数生长期,在0.01M pH 7.2磷酸盐缓冲液中稀释至106-7CFU/mL。将抗菌肽PV-Q5溶于磷酸盐缓冲中,再等体积与菌液混合后,分别进行静置、微电压(10V)处理。将在37℃培养箱中静置2小时的作为空白对照组,将在37℃培养箱中静置通入10V的微电压处理2小时的作为样品组,培养2小时后涂平板,平板在37℃培养箱中静置过夜。如图2和图3所示,图2为本发明抗菌肽PV-Q5单独处理对副溶血性弧菌最低抑制浓度(MIC)测定对照图,其中,图2和图3的A:空白组抗菌肽浓度500μg/mL;B:空白组抗菌肽浓度125μg/mL;C:空白组抗菌肽浓度62.5μg/mL;D:空白组抗菌肽浓度31.25μg/mL。E:空白组抗菌肽浓度15.62μg/mL。图3是抗菌肽PV-Q5培养箱静置2h协同微电流(10V)对副溶血性弧菌最低抑制浓度(MIC)测定图。可以看出,抗菌肽PV-Q5在培养箱中2小时后对副溶血性弧菌的MIC为31.25μg/mL、抗菌肽PV-Q5经过微电压处理2小时后对副溶血性弧菌的MIC为15.62μg/mL。
实施例4:时间杀伤曲线测定
将副溶血性弧菌在37℃培养12h至对数生长期,在0.01M pH 7.2磷酸盐缓冲液中稀释至106-7CFU/mL。取MIC浓度肽PV-Q5等体积与菌混合后在37℃分别进行静置、微电压(10V)处理。将在37℃培养箱中静置的作为空白对照组,将在37℃培养箱中静置通入10V的微电压的作为样品组。每隔30分钟分别取出空白组和样品组涂平板,37℃培养过夜后记录菌落总数。结果见图4,图4为时间杀伤曲线为副溶血性弧菌。(●)为抗菌肽PV-Q5在孵育处理下的时间杀伤曲线,(▲)为抗菌肽PV-Q5在微电压处理下的时间杀伤曲线。由结果可知,无论是抗菌肽PV-Q5单独处理副溶血性弧菌,或微电压辅助处理抗菌肽PV-Q5对副溶血性弧菌时的作用效果,均在2小时内达到顶峰,随后趋于平缓,但微电压辅助处理抗菌肽PV-Q5明显优于抗菌肽PV-Q5单独处理。
实施例5:透射电镜分析
以106-7CFU/mL的细菌在37℃下用2×MIC的抗菌肽PV-Q5处理2小时,然后在2700g下离心10min,用磷酸盐缓冲液(pH 7.2)洗涤两次。用1%的锇酸固定后,用95%乙醇脱水,然后丙酮处理20min。样品在70℃下烘烤24h,在铜网格上制备70-90nm的薄片,然后用柠檬酸铅和乙酸铀酯染色。用H-7650透射电子显微镜观察和捕获超微结构。
以未处理的细菌细胞作为空白对照组,将抗菌肽PV-Q5单独作用副溶血性弧菌2小时和抗菌肽PV-Q5作用副溶血性弧菌同时通入微电压(10v)作用2小时为样品组。为探究抗菌肽PV-Q5和抗菌肽PV-Q5协同微电压对细菌超微结构的影响,使用透射电镜观察其中的变化。结果见图5,抗菌肽PV-Q5作用副溶血性弧菌的透射电镜图,其中A为:副溶血性弧菌空白对照组;B为抗菌肽PV-Q5处理2h后的副溶血性弧菌;C为抗菌肽PV-Q5微电压处理2h后的副溶血性弧菌。可以看出:空白对照组显示组织分布均匀,无渗漏,表面细胞膜光滑(A)。用抗菌肽PV-Q5处理后,副溶血性弧菌的细胞膜出现一些模糊和不规则,细胞内溶质渗漏(B)。然而抗菌肽PV-Q5协同微电压处理后细菌细胞内溶质渗漏、细胞破裂(C)。这进一步证实了在微电压的条件下能够辅助抗菌肽PV-Q5通过破坏细胞膜的方式进行杀菌。
实施例6:抗菌肽PV-Q5对细菌细胞膜通透性的影响
为了研究抗菌肽PV-Q5对副溶血性弧菌通透性的影响,将细菌置于1×MIC浓度的抗菌肽PV-Q5下培养,观察其对细菌细胞膜通透性的影响。具体操作如下:通过离心收集副溶血性弧菌细胞,再重悬于以乳糖为唯一碳源的M9培养基中,37℃摇床培养至OD600nm<0.4。将混合物加入96孔平底板中,在37℃下孵育,然后加入0.5mg/mL的ONPG(2-硝基苯基-β-D-吡喃半乳糖苷)混匀后进行摇床培养观察并测定其在(0-8h)的OD42nm0的变化,如图6所示。图6是抗菌肽PV-Q5作用副溶血性弧菌的细胞膜通透性图。
抗菌肽PV-Q5作用副溶血性弧菌后能明显观察到副溶血性弧菌的细胞膜通透性增加。细胞壁(膜)结构完整对维持细胞形态与胞内环境有重要作用,受损时可引起细胞通透性增强甚至出现不可逆孔洞,造成胞内离子及生物大分子物质泄露并诱导细胞凋亡。
实施例7:圆二色谱测定抗菌肽PV-Q5的二级结构
用Chirascan V100圆二色谱仪在25℃下以100nm/min的扫描速度测定了肽的平均残基摩尔椭圆度。将抗菌肽PV-Q5溶于25mM十二烷基硫酸钠(SDS)中,溶液最终浓度为0.20mg/mL。抗菌肽PV-Q5在0.01M pH 7.2磷酸盐缓冲液(PBS)中的情况下同一处理作为对照。
CD光谱可以检测抗菌肽在不同溶液中的二级结构。抗菌肽PV-Q5在0.01M pH7.2PBS和0.20mg/mL SDS溶液中的CD光谱如图7所示。图7是抗菌肽PV-Q5圆二色谱图。抗菌肽PV-Q5在PBS体系中波长200nm附近有负的吸收峰,符合无规则卷曲的特征吸收峰,其二级结构为无规则卷曲;抗菌肽PV-Q5在SDS体系中时,波长190nm处附近有正的吸收峰、200nm和220nm处附近有负的吸收峰,符合α-螺旋的特征吸收。表明PV-Q5在模拟细胞膜环境中,以α-螺旋结构存在。
α-螺旋中的亲水侧链和疏水侧链分别处于螺旋的两侧,这一特殊结构会促进生物膜和多肽片段相互作用。当抗菌肽与细菌的细胞膜结合时,α-螺旋会相互聚集,在细胞膜表面形成孔洞,造成细胞质密度降低、内容物流出,细胞死亡。
实施例8:抗菌肽PV-Q5的三维结构预测
利用在线结构预测服务器I-Tasser对凡纳滨对虾抗菌肽PV-Q5的三维结构进行预测。得到凡纳滨对虾中抗菌肽PV-Q5三维结构如图8所示。图8是抗菌肽PV-Q5的三维结构预测图。
尽管上面已经示出和描述了本发明的实施例,可以理解的是,上述实施例是示例性的,不能理解为对本发明的限制,本领域的普通技术人员在不脱离本发明的原理和宗旨的情况下在本发明的范围内可以对上述实施例进行变化、修改、替换和变型。
SEQUENCE LISTING
<110> 集美大学
<120> 一种微电压方法协同抗菌肽PV-Q5及其用途
<130> JMDXL-21055-CNI
<160> 10
<170> PatentIn version 3.5
<210> 1
<211> 10
<212> PRT
<213> 凡纳滨对虾(Penaeus vannamei)
<400> 1
Thr Arg Glu Gln Leu Ala Glu Glu Lys Lys
<210> 2
<211> 9
<212> PRT
<213> 凡纳滨对虾(Penaeus vannamei)
<400> 2
His Ala Asp Ala Gln Lys Asn Leu Arg
<210> 3
<211> 9
<212> PRT
<213> 凡纳滨对虾(Penaeus vannamei)
<400> 3
Lys Ala Ile Ser Ser Leu Glu Ala Arg
<210> 4
<211> 12
<212> PRT
<213> 凡纳滨对虾(Penaeus vannamei)
<400> 4
Lys Asp Ala Tyr Val Gly Asp Glu Ala Gln Ser Lys
<210> 5
<211> 20
<212> PRT
<213> 凡纳滨对虾(Penaeus vannamei)
<400> 5
Gln Val Arg Asn Phe Pro Arg Gly Ser Ala Ala Ser Pro Ser Ala Leu
Ala Ser Pro Arg
<210> 6
<211> 18
<212> PRT
<213> 凡纳滨对虾(Penaeus vannamei)
<400> 6
Thr Gly Ser Asn Val Phe Asp Met Phe Thr Gln Lys Gln Val Ala Glu
Phe Lys
<210> 7
<211> 18
<212> PRT
<213> 凡纳滨对虾(Penaeus vannamei)
<400> 7
Arg Gln Ile Glu Glu Ala Glu Glu Ile Ala Ala Leu Asn Leu Ala Lys
Tyr Arg
<210> 8
<211> 17
<212> PRT
<213> 凡纳滨对虾(Penaeus vannamei)
<400> 8
Arg Glu Val Phe Glu Leu Gly Gly Val Thr His Leu Leu Asn Val Leu
Lys
<210> 9
<211> 19
<212> PRT
<213> 凡纳滨对虾(Penaeus vannamei)
<400> 9
Ala Gly Phe Ala Gly Asp Asp Ala Pro Arg Ala Val Phe Pro Ser Ile
Val Gly Arg
<210> 10
<211> 12
<212> PRT
<213> 凡纳滨对虾(Penaeus vannamei)
<400> 10
Ile Gln Glu Lys Glu Glu Glu Phe Asp Ala Thr Arg
Claims (10)
1.一种抗菌肽PV-Q5,其特征在于,所述抗菌肽PV-Q5的氨基酸序列如SEQ ID NO:5所示。
2.权利要求1所述抗菌肽PV-Q5用于抗菌的用途。
3.如权利要求2所述的用途,其特征在于,所述菌是指细菌。
4.如权利要求3所述的用途,其特征在于,所述细菌是指副溶血性弧菌和大肠杆菌。
5.如权利要求3所述的用途,其特征在于,所述抗菌是指抑制和/或杀灭副溶血性弧菌、大肠杆菌。
6.如权利要求2所述的用途,其特征在于,所述抗菌在微电压辅助处理下,具有增强的效果。
7.权利要求1所述抗菌肽PV-Q5具有改变菌细胞膜表面通透性的用途。
8.权利要求1所述抗菌肽PV-Q5用于制备抗菌药物、食品防腐剂和水产动物养殖饲料的用途。
9.一种抗菌药物,其特征在于,含有权利要求1所述抗菌肽PV-Q5。
10.一种食品防腐剂,其特征在于,含有权利要求1所述抗菌肽PV-Q5。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111659224.XA CN114409754B (zh) | 2021-12-30 | 2021-12-30 | 一种微电压方法协同抗菌肽pv-q5及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111659224.XA CN114409754B (zh) | 2021-12-30 | 2021-12-30 | 一种微电压方法协同抗菌肽pv-q5及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114409754A true CN114409754A (zh) | 2022-04-29 |
CN114409754B CN114409754B (zh) | 2023-09-12 |
Family
ID=81269544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111659224.XA Active CN114409754B (zh) | 2021-12-30 | 2021-12-30 | 一种微电压方法协同抗菌肽pv-q5及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114409754B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019241938A1 (zh) * | 2018-06-20 | 2019-12-26 | 厦门大学 | 一种拟穴青蟹抗菌肽Sparamosin及其应用 |
CN112898386A (zh) * | 2021-03-02 | 2021-06-04 | 集美大学 | 一种大黄鱼肌球蛋白重链抗菌肽lcmhc及其应用 |
CN113087771A (zh) * | 2021-04-25 | 2021-07-09 | 集美大学 | 一种南美白对dna结合抗菌肽vpdb40及其应用 |
-
2021
- 2021-12-30 CN CN202111659224.XA patent/CN114409754B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019241938A1 (zh) * | 2018-06-20 | 2019-12-26 | 厦门大学 | 一种拟穴青蟹抗菌肽Sparamosin及其应用 |
CN112898386A (zh) * | 2021-03-02 | 2021-06-04 | 集美大学 | 一种大黄鱼肌球蛋白重链抗菌肽lcmhc及其应用 |
CN113087771A (zh) * | 2021-04-25 | 2021-07-09 | 集美大学 | 一种南美白对dna结合抗菌肽vpdb40及其应用 |
Non-Patent Citations (1)
Title |
---|
JINGYI DAI等: "Antibacterial Activity and Mechanism of Peptide PV-Q5 against Vibrio parahaemolyticus and Escherichia coli, Derived from Salt-Fermented Penaeus vannamei", FOODS, vol. 12, no. 9, pages 1804 * |
Also Published As
Publication number | Publication date |
---|---|
CN114409754B (zh) | 2023-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Szekeres et al. | Peptaibols and related peptaibiotics of Trichoderma | |
Xiao et al. | Efficient screening of a novel antimicrobial peptide from Jatropha curcas by cell membrane affinity chromatography | |
Sood et al. | Paenilarvins: Iturin family lipopeptides from the honey bee pathogen Paenibacillus larvae | |
CN112898386B (zh) | 一种大黄鱼肌球蛋白重链抗菌肽lcmhc及其应用 | |
CN114395026B (zh) | 一种基于理性设计策略构建的广谱抗菌肽 | |
CN107298706B (zh) | 一种荷斯坦奶牛脾脏源抗菌肽及其制备方法与应用 | |
Varnava et al. | A review on comparative mechanistic studies of antimicrobial peptides against archaea | |
Ramachander Turaga | Peptaibols: antimicrobial peptides from fungi | |
Miyoshi et al. | Functional structure and antimicrobial activity of persulcatusin, an antimicrobial peptide from the hard tick Ixodes persulcatus | |
Song et al. | Identification of new dermaseptins with self-assembly tendency: Membrane disruption, biofilm eradication, and infected wound healing efficacy | |
Singh et al. | Characterization of iturin v, a novel antimicrobial lipopeptide from a potential probiotic strain Lactobacillus sp. M31 | |
CN114409754B (zh) | 一种微电压方法协同抗菌肽pv-q5及其用途 | |
CN116640186A (zh) | 一种人鼻液补体因子抗菌肽c4-aⅱ及其应用 | |
CN117164665A (zh) | 一种人鼻液α-2-巨球蛋白抗菌肽A2M3及其应用 | |
Kong et al. | Insights into the antibacterial activity of cottonseed protein-derived peptide against Escherichia coli | |
CN114773435A (zh) | 一种蚯蚓抗菌肽及其在广谱抗菌方面的应用 | |
Zhang et al. | A novel endogenous antimicrobial peptide MP-4 derived from koumiss of Inner Mongolia by peptidomics, and effects on Staphylococcus aureus | |
CN114516899A (zh) | 抗菌肽yhx-5及其应用 | |
CN114380893B (zh) | 一种腌制凡纳滨对虾抗菌肽ec-v10及其用途 | |
AU2015274889B2 (en) | Antimicrobial peptides, pharmaceutical compositions, and methods of use thereof | |
CN109627285B (zh) | 迦得拟微绿球藻抗菌肽及其应用 | |
Shanmugaraju et al. | Partial purification and characterization of Anti-MRSA peptide from marine Pseudomonas aeruginosa | |
CN113025518A (zh) | 一种产细菌素的发酵乳杆菌及其在抑制发酵食品产白膜中的应用 | |
CN114478734B (zh) | 一种可协同NaCl的凡纳滨对虾抗菌肽GPCR10及其用途 | |
Tabarez | Discovery of the new antimicrobial compound 7-O-malonyl macrolactin A |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |